Status:
UNKNOWN
Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group
Collaborating Sponsors:
HalioDx
Methodology and quality of life unit in oncology, University hospital of Besancon
Conditions:
Colorectal Cancer
Stage III Colon Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective is to validate that the Immunoscore® test (IS0 to IS4) is able to identify patients with high risk (IS 0-1) of relapse or death whichever occurs first among Stage III patients un...
Detailed Description
Adult patients of both genders who have underwent surgical resection of stage III colon carcinoma and randomised to receive a 6-month or 3-month adjuvant therapy with modified FOLFOX 6 or CAPOX in the...
Eligibility Criteria
Inclusion
- Patient and tumor characteristics; 3-year clinical Follow-Up
- Data regarding other markers (eg. MSI)
- FFPE blocks available, including core tumor + invasive margin regions
Exclusion
- • Bouin fixative
- Sample type:
- • adjacent FFPE slices (4 μm each) per case (although only one slide is required for CD3 and one for CD8, with center of tumor (CT) and the invasive margin(IM) cut from FFPE blocks no more than 4 months before the Immunoscore® testing
Key Trial Info
Start Date :
July 13 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 15 2019
Estimated Enrollment :
1122 Patients enrolled
Trial Details
Trial ID
NCT03422601
Start Date
July 13 2017
End Date
July 15 2019
Last Update
February 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Saint Antoine
Paris, France